Asked by: Lord Lebedev (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the evidence-base for the use of ketamine to treat trauma-related mental health conditions, and whether they plan to provide such treatments through NHS mental health services.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Ketamine does not have a marketing authorisation in the United Kingdom for use in the treatment of any mental health conditions. Esketamine nasal spray, an isomer of ketamine, is licensed for treatment-resistant depression that has not responded to at least two different antidepressants in the current moderate to severe depressive episode in adults, and for the treatment of adults with a moderate to severe episode of major depressive disorder, as acute short-term treatment for the rapid reduction of depressive symptoms, which, according to clinical judgement, constitutes a psychiatric emergency.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new, licenced medicines represent a clinically and cost-effective use of resources.
The NICE has been unable to recommend esketamine for treatment-resistant depression due to uncertainties in its clinical and cost-effectiveness. It is not therefore routinely funded by the NHS in England for any indication.
The NICE was unable to make recommendations on the use of esketamine nasal spray for the treatment of major depressive disorder because the marketing authorisation holder did not provide an evidence submission.
Asked by: Lord Lebedev (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the potential neurodevelopmental impacts in children from prolonged screen time using mobile phones and social media, and how any such assessment informs public health guidance for families and schools.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2018, the United Kingdom’s Chief Medical Officer commissioned independent researchers at University College London to map published research on screen time, social media, and children and young people’s mental health. Their findings were published by the National Institute for Health Research.
On 7 February 2019, the Chief Medical Officer published a commentary on this research, alongside their advice for parents and carers, and their recommendations for other stakeholders. They determined that the evidence was insufficiently conclusive to support the Chief Medical Officer’s evidence-based guidelines on optimal amounts of screen use or online activities, such as social media use.
Asked by: Lord Lebedev (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the use of psychedelics in the treatment of mental health; and what steps they are taking to support advanced research in this sector.
Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)
The Medicines and Healthcare products Regulatory Agency (MHRA) has conducted scientific advice meetings with research organisations developing drugs with psychedelic properties for the treatment of mental health conditions. The MHRA does not conduct research, however they enable clinical trials research to take place and have procedures in place to review marketing authorisation applications submitted to them, with regard to the drug’s quality, safety and effectiveness.
The Department of Health and Social Care commissions research through the National Institute for Health and Care Research (NIHR), which has invested £1.1 million in a randomised controlled trial to examine the feasibility, safety and efficacy of the use of psilocybin in people with treatment-resistant depression.
The NIHR also invests in psychedelic-assisted psychotherapies through its infrastructure. For example, the Imperial Biomedical Research Centre aims to investigate the potential of treating psychiatric disorders with psychedelics. The NIHR welcomes funding applications for research into any aspect of human health, including psychedelic-assisted psychotherapies.
Asked by: Lord Lebedev (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what discussions they have had with social media companies about protecting the mental health of under-16s, especially girls, using their platforms.
Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)
The Department met with TikTok and Meta in December 2022 and January 2023, to discuss the mental health of children and young people, including girls who are under 16 years old.